8-K filed January 9, 2026, 6:59 PM ET ticker LONA CIK 0001620463

other material confidence high sentiment neutral materiality 0.50

Athira Pharma renames to LeonaBio (LONA); lasofoxifene Phase 3 >50% enrolled; CFO gets new severance

LeonaBio, Inc.

Name change to LeonaBio effective Jan 9, 2026; ticker to LONA on Nasdaq starting Jan 12.
Phase 3 ELAINE-3 trial of lasofoxifene >50% enrolled; topline data expected mid-2027.
CFO Robert Renninger entered amended change in control severance agreement; base salary increased to $460,000.
Name change reflects Dec 2025 acquisition of lasofoxifene rights, with $90M upfront financing and potential additional $146M.

item 5.03 item 7.01 item 8.01 item 5.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-008904
form_type: 8-K
ticker: LONA
cik: 0001620463
company_name: LeonaBio, Inc.
filed_at: 2026-01-09T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.659049+00:00
generated_at: 2026-05-16T11:03:58.087357+00:00
sec_items: ["5.03", "7.01", "8.01", "5.02", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-008904
json_url: https://secwatch.observer/filing/0001193125-26-008904.json
markdown_url: https://secwatch.observer/filing/0001193125-26-008904.md
text_url: https://secwatch.observer/filing/0001193125-26-008904.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1620463/000119312526008904/0001193125-26-008904-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1620463/000119312526008904/atha-20260107.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

312235b1bf84c3e1e05e8ef2a22d0f7858c6b515

LeonaBio, Inc.: Certificate of Amendment to Amended and Restated Certificate of Incorporation to change corporate name from Athira Pharma, Inc. to LeonaBio, Inc (effective 2026-01-09).

Effective January 9, 2026, Athira Pharma, Inc. (the “Company”) changed its name to LeonaBio, Inc. (the “Name Change”). The Name Change was approved by the Company’s Board of Directors (the “Board”) and was effectuated through the filing of a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation with the Delaware Secretary of State.

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

69eae61f6a6e9483c12cc498b59fe6d70dee29ad

LeonaBio, Inc.: Amended and restated bylaws to reflect the name change to LeonaBio, Inc (effective 2026-01-09).

Additionally, effective January 9, 2026, the Board approved an amendment and restatement of the Company’s bylaws (the “Amended and Restated Bylaws”) to reflect the Name Change.

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

Comparable filings

MTNE

CH4 Natural Solutions Corporation prices $200M IPO; begins trading on NYSE

CH4 Natural Solutions Corp May 5, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 7.01, 8.01, 9.01

same fact type: governance_change same SEC item: 5.02, 5.03, 7.01, 8.01, 9.01 same event type: other_material similar materiality

This filing

Effective January 9, 2026, Athira Pharma, Inc. (the “Company”) changed its name to LeonaBio, Inc. (the “Name Change”). The Name Change was approved by the Company’s Board of Directors (the “Board”) and was effectuated through the filing of a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation with the Delaware Secretary of State.

Comparable filing

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. The Company’s Amended and Restated Memorandum and Articles of Association (as so amended, the “ Memorandum and Articles ”) were approved on April 30, 2026.

Filing page SEC filing

QXL

Viewbix renamed Quantum X Labs Inc.; Nasdaq ticker changes to QXL

Viewbix Inc. April 30, 2026, 7:59 PM ET other_material Items 5.03, 7.01, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 7.01, 8.01, 9.01 same event type: other_material similar materiality

This filing

Effective January 9, 2026, Athira Pharma, Inc. (the “Company”) changed its name to LeonaBio, Inc. (the “Name Change”). The Name Change was approved by the Company’s Board of Directors (the “Board”) and was effectuated through the filing of a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation with the Delaware Secretary of State.

Comparable filing

effective April 30, 2026, the Company amended and restated its Amended and Restated Bylaws (the "Bylaws") to reflect the Name Change (the "A&R Bylaws"). The A&R Bylaws contain no other changes.

Filing page SEC filing

DCOM

Dime Commercial Bancshares name change effective; three executives amend employment agreements

Dime Community Bancshares, Inc. /NY/ June 1, 2026, 4:02 PM ET other_material Items 5.02, 5.03, 5.07, 9.01

same fact type: governance_change same SEC item: 5.02, 5.03, 9.01 same event type: other_material similar materiality

This filing

Effective January 9, 2026, Athira Pharma, Inc. (the “Company”) changed its name to LeonaBio, Inc. (the “Name Change”). The Name Change was approved by the Company’s Board of Directors (the “Board”) and was effectuated through the filing of a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation with the Delaware Secretary of State.

Comparable filing

On May 28, 2026, the Company filed with the Department of State of the State of New York a Certificate of Amendment to Certificate of Incorporation to change our corporate name from Dime Community Bancshares, Inc. to Dime Commercial Bancshares, Inc., effective immediate.

Filing page SEC filing

CPSH

CPS Technologies closes $9.6M registered direct offering of 1.2M shares at $8.00/share

CPS TECHNOLOGIES CORP/DE/ June 1, 2026, 9:35 AM ET other_material Items 1.01, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

Effective January 9, 2026, Athira Pharma, Inc. (the “Company”) changed its name to LeonaBio, Inc. (the “Name Change”). The Name Change was approved by the Company’s Board of Directors (the “Board”) and was effectuated through the filing of a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation with the Delaware Secretary of State.

Comparable filing

On May 27, 2026, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Amendment”) of the Company’s Restated Certificate of Incorporation, effective as of the same date. The Amendment increased the number of shares of common stock, $0.01 par value per share (the “Common Stock”), that the Company is authorized to issue from 20,000,000 to 25,000,000.

Filing page SEC filing

RDAC

Shareholders approve SPAC extension to Oct 15, 2027; ~1.9M shares redeemed

Rising Dragon Acquisition Corp. June 1, 2026, 6:08 AM ET other_material Items 1.01, 5.03, 5.07, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

Effective January 9, 2026, Athira Pharma, Inc. (the “Company”) changed its name to LeonaBio, Inc. (the “Name Change”). The Name Change was approved by the Company’s Board of Directors (the “Board”) and was effectuated through the filing of a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation with the Delaware Secretary of State.

Comparable filing

Subsequent to the approval by its shareholders at the Extension Meeting of Rising Dragon’s second amended and restated memorandum and articles of association (the “Amended Charter”), the Company filed the Amended Charter with the Cayman Islands Registrar of Companies, effective May 28, 2026

Filing page SEC filing

AEIS

AEIS stockholders approve doubling of authorized shares to 140M and expansion of equity plan to 4.9M shares

ADVANCED ENERGY INDUSTRIES INC May 8, 2026, 7:59 PM ET other_material Items 5.02, 5.07, 5.03, 9.01

same fact type: governance_change same SEC item: 5.02, 5.03, 9.01 same event type: other_material similar materiality

This filing

Effective January 9, 2026, Athira Pharma, Inc. (the “Company”) changed its name to LeonaBio, Inc. (the “Name Change”). The Name Change was approved by the Company’s Board of Directors (the “Board”) and was effectuated through the filing of a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation with the Delaware Secretary of State.

Comparable filing

the amendment increases the number of authorized shares of common stock from 70,000,000 shares to 140,000,000 shares. The amendment became effective upon the filing of a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware on May 7, 2026.

Filing page SEC filing

WAMFF

Alaska Silver simplifies capital structure, eliminates dual-class shares

Alaska Silver Corp. May 7, 2026, 7:59 PM ET other_material Items 3.03, 5.03, 7.01, 9.01

same fact type: governance_change same SEC item: 5.03, 7.01, 9.01 same event type: other_material similar materiality

This filing

Effective January 9, 2026, Athira Pharma, Inc. (the “Company”) changed its name to LeonaBio, Inc. (the “Name Change”). The Name Change was approved by the Company’s Board of Directors (the “Board”) and was effectuated through the filing of a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation with the Delaware Secretary of State.

Comparable filing

On May 6, 2026, the Board of Directors of Alaska Silver Corp. (the "Company"), approved an amendment (the "Amendment") to the Company's Articles of the Company to eliminate its dual-class share structure by (i) eliminating its proportionate voting share class and (ii) reidentifying its subordinate voting share class as the class of "Common Shares," no par value, of which the Company shall be authorized to issue an unlimited number of Common Shares.

Filing page SEC filing

JPM

JPMorgan issues $3B of 6.100% Fixed-Rate Reset Non-Cumulative Preferred Stock, Series PP

JPMORGAN CHASE & CO May 7, 2026, 7:59 PM ET other_material Items 3.03, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

Effective January 9, 2026, Athira Pharma, Inc. (the “Company”) changed its name to LeonaBio, Inc. (the “Name Change”). The Name Change was approved by the Company’s Board of Directors (the “Board”) and was effectuated through the filing of a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation with the Delaware Secretary of State.

Comparable filing

On May 6, 2026, the Company filed a Certificate of Designations, Powers, Preferences and Rights with the Secretary of State of the State of Delaware, establishing the rights, preferences, privileges, qualifications, restrictions and limitations relating to the Series PP Preferred Stock

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-26-008904

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.